Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 1422Pancreatic Neoplasms 847Carcinoma, Hepatocellular 736Stomach Neoplasms 639Colonic Neoplasms 441Rectal Neoplasms 400Esophageal Neoplasms 395Carcinoma, Non-Small-Cell Lung 328Breast Neoplasms 328Neoplasms 300Liver Neoplasms 280Cholangiocarcinoma 242Ovarian Neoplasms 240Lung Neoplasms 238Neoplasm Metastasis 237Gastrointestinal Neoplasms 216Melanoma 184Prostatic Neoplasms 162Esophageal Squamous Cell Carcinoma 160Biliary Tract Neoplasms 160Endometrial Neoplasms 141Squamous Cell Carcinoma of Head and Neck 128Uterine Cervical Neoplasms 127Carcinoma, Renal Cell 113Head and Neck Neoplasms 112Sarcoma 100Urinary Bladder Neoplasms 95Adenocarcinoma Of Esophagus 89Triple Negative Breast Neoplasms 84Anus Neoplasms 83

Interventions

durvalumab 2Gemcitabine 2titanium silicide 1regorafenib 1pembrolizumab 1Nivolumab 1Injections 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Biliary Tract Cancer × Gastrointestinal × 1 year × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT04781192 2026-01-23

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

University of Kansas Medical Center

Phase 1/2 Active not recruiting
40 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡